Overview

Genetic Epidemiology of Responses to Antihypertensives

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
0
Participant gender:
All
Summary
To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Antihypertensive Agents
Candesartan
Candesartan cilexetil
Hydrochlorothiazide
Criteria
Primary (essential) hypertension